ESC Premium Access

Stroke severity and subsequent mortality are worse with atrial fibrillation than in patients without atrial fibrillation

Congress Presentation

About the speaker

Ms Naja Emborg Vinding

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
0 follower

5 more presentations in this session

Comparative safety and effectiveness of standard doses of apixaban versus dabigatran, rivaroxaban, and VKAs in non-valvular atrial fibrillation patients in France: the NAXOS study

Speaker: Professor N. Danchin (Paris, FR)

Thumbnail

Resumption of anticoagulant treatment in patients with atrial fibrillation following gastrointestinal bleeding: a nationwide cohort study

Speaker: Miss D. Rajan (Copenhagen, DK)

Thumbnail

ETNA-AF Europe: First 1-year follow-up snapshot analysis of more than 7,500 AF patients treated with edoxaban in routine clinical practice

Speaker: Professor R. De Caterina (Pisa, IT)

Thumbnail

Left atrial dimension and risk of cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis

Speaker: Doctor P. Meyre (Basel, CH)

Thumbnail

Right atrial low voltage zone as a novel predictor of sinus node dysfunction in patients with non-paroxysmal atrial fibrillation

Speaker: Doctor T. Kondo (Hiroshima, JP)

Thumbnail

Access the full session

Identifying and managing complications of atrial fibrillation

Speakers: Ms N. Vinding, Professor N. Danchin, Miss D. Rajan, Professor R. De Caterina, Doctor P. Meyre...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk